anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE: A transglutaminase inhibitor containing oltipraz is provided to prevent or treat diseases caused by transglutaminase activation without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating diseases caused by transglutaminase activation contains oltipraz or pharmaceutically acceptable salt. The diseases are inflammatory diseases, cancers, or neurological disorders. The inflammatory diseases are chronic inflammatory disorder such as degenerative arthritis, septicemia, or autoimmune myositis. The neurological disorder is Alzheimer disease, Huntington disease, or Parkinson&#39;s disease. The composition and treatment using the same are applied to mammals such as human, pig, camel, dog, horse, sheep, and cat.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide effective means for inducing immune tolerance mediated by antigen-specific T cells.  &lt;P&gt;SOLUTION: An immune tolerance inducer contains an apoptosis induction product of a cell having an antigen bound to the cell surface as an active ingredient. A prophylactic agent of autoimmune diseases contains the apoptosis induction product as an active ingredient. A prophylactic agent for allergy contains the apoptosis induction product as an active ingredient. In a method of preparing the immune tolerance inducer, the prophylactic agent for autoimmune diseases or the prophylactic agent for allergy includes a step of culturing the cell having the antigen bound to the cell surface and a step of inducing apoptosis of the cultured cell to prepare the apoptosis induction product of the cell.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The present invention relates to a medicine for treating acute and chronic bronchial asthma and cough and a preparation process thereof, more specifically Chinese patent medicine which is prepared by using Chinese herbal medicine as raw materials. Medicinal wine named &#39;the medicinal wine of Dong Jia&#39; is prepared form more than ten kinds of Chinese herbal medicine, such as angelica, chuanxiong rhizome, broomrape, epimedium, european grape root, yangtao actinidia root, etc. The medicinal wine has good effect on relieving cough and asthma under the principal of enhancing the total disease resisting function of human bodies. The medicinal wine of the present invention can have two preparation methods of family soaking preparation and industrial production, wherein the industrial production method is that the medicine and foodstuffs are jointly fermented and brewed. The product of the present invention is not only a health-care product, but also the medicine and has no toxic or side effect. The medicine of the present invention has the functions of promoting appetite, strengthening the spleen, eliminating wind, eliminating dampness, nourishing Yin and strengthening Yang.
The invention belongs to the field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for healing a haemorrhoid postoperative wound and a preparation method thereof. The traditional Chinese medicine composition is composed of medicine for oral administration and medicine for external use. The medicine for oral administration is prepared from the root of clerodendron bungei steud, sheepear inula herb, gymnadnia conopsear broyn, herb of white clover, the root of bidentate achyranthes, safflower carthamus, peach kernels, elecampane and gallnuts. The medicine for external use is prepared from peperomia blanda, borneol, cutch, dragon&#39;s blood, golden cypress, field pennycress and Chinese violet. The medicine for oral administration has the effects of promoting blood circulation to remove blood stasis, inducing diuresis and reducing edema, and stopping bleeding and relieving pain. The medicine for external use has the effects of dispelling dampness and resolving toxin, promoting blood circulation to remove blood stasis, and relieving swelling and pain. According to the traditional Chinese medicine composition, by combining oral administration and external use, local circulation can be improved, tissue nutrition can be added, granulation growth is accelerated, and therefore the effect of healing the postoperative wound as soon as possible is achieved; both haemorrhoid causes and haemorrhoid postoperative pathological changes are considered, and the effect is remarkable.
Both alkenyl isothiocyanates of formula   &lt;IMAGE&gt; where R is hydrogen hydrocarbyl or substituted hydrocarbyl, at least one R having 6-10,000 carbon atoms, and also thiocarbamyl derivatives of such compounds, are useful as additives for fuels and lubricants. The isothiocyanates may be made either by reacting an alkenyl chloride, e.g. chlorinated polyisobutylene, with KSCN to form a thiocyanate which then isomerises to the isothiocyanate, or by reacting an alkene, e.g. diisobutene, polyisobutene, isobutene/isoprene copolymer or EPDM, with Cl.SCN, removing HCl from the adduct to produce a thiocyanate, and then effecting thermal rearrangement to the isothiocyanate. The thiocarbamyl derivatives may be made by reacting the isothiocyanate with a reactive hydrogen compound, e.g. diethylene triamine, tetraethylene pentamine, benzylamine, N-aminopropyl morpholine, tris(hydroxymethyl)- aminomethane or 1,4,8,11- tetraazacyclotetradecane.
PURPOSE:To obtain a foundation cosmetic capable of improving makeup durability with usability having refreshing feeling by blending a low-viscosity silicone with high-viscosity and/or solid silicone in an oily phase and emulsifying the resultant blend according to a specific method. CONSTITUTION:A foundation cosmetic obtained by adding a hydrophilic surfactant into a water-soluble solvent and blending the resultant solution with a silicone having &lt;=50cP viscosity at 25 deg.C and a silicone having &gt;=500cP viscosity at 25 deg.C and/or a silicone which is a solid at ordinary temperature. The amount of the blended hydrophilic surfactant is 0.01-5wt.% and total amount of the blended water-soluble solvent the hydrophilic surfactant is &gt;=20wt.% based on the oily phase ingredient. The silicones are blended in an amount of &gt;=30wt.% based on the oily phase. Emulsification is performed in the aforementioned oil-water-soluble solvent system as the first stage to prepare an oil-in-water-soluble solvent type emulsion, which is then added to an aqueous phase to stabilize the emulsion as the second stage. Thereby, the objective substance is obtained.
PURPOSE:The titled tea comprising leaves or stems of ginseng as an essential component. CONSTITUTION:Leaves and/or stems of ginseng (e.g., Panax ginseng C.A.Mayer, Panax japonicus C.A.Myer, Panax quinquefol ium Linne, etc.) are collected, thinly cut, washed, boiled or steamed (to make raw material soft and to deactivate oxidase) and/or roasted. In the roasting process, the ginseng is preheated at 150-400 deg.C in a container and roasted in the container for the required time (&lt;=several minutes at 300 deg.C of &lt;=1hr at about 200 deg.C). Then, rubbing is carried out at 10-60min without heating. Furthermore, the ginseng is dried in the sun for a week or dried at 40-90 deg.C by hot-air drying to give ginseng tea. The ginseng tea may be further blended with a component such as ginseng powder, Gynostemma pentaphyllum Makino, oolong tea, adlay tea, etc. EFFECT:A saponin component is effectively extracted and the tea is administered while preventing a particular drug smell and astringency.
O6-Benzylated guanine guanosine and 2&#39;-deoxyguanosine compounds of formula (1), wherein Z is hydrogen, (.alpha.) or (.beta.), and R is a benzyl group or a substituted benzyl group. cause a depletion of O6-alkylguanine-DNA alkyltransferase (AGT) activity in mammalian cells. These compounds may be administered to a host so as to reduce AGT levels in tumor cells of the host in order to increase host responsiveness to anti-neoplastic alkylating agents. including chloroethylating agents, such as chloroethylnitrosoureas, for chemotherapeutic treatment of a number of neoplasms.
Prepn. of a salt of N-acetylglutamic acid (I) comprises neutralising (I) with a basic cpd. of a divalent metal, pref. Ca(OH)2. Pref. an aq. soln. is prepd., then the salt is pptd. by adding an organic solvent (pref. methanol, ethanol or acetone), recovered and dried at 105 degrees C. Alternatively, the aq. soln. is filtered, filled into containers and sterilised by heating. Other water sol. salts, pref. MgC 12, and &gt;=1 preservative may be added to the soln. Soln. can be given by intravenous or intramuscular injections and infusions in Ca therapy or, when combined with other active ingredients such as Mg salts, in treatment of tetany in ruminants. The Ca salt of (I) is readily soluble in water, has a bland taste, is well tolerated, of low toxicity (i.e. LD50 in mice is 800 mg/kg on Ca basis), readily resorbed and very stable. It requires no toxic auxiliaries such as boric acid.
A medical information retrieval system comprises a natural language processing system that processes a vocal user query to identify key words and phrases. These key words and phrases are provided to an inferencing engine that provides a set of knowledge-based inferences from medical knowledge sources, based on these key words and phrases. Thereafter, these knowledge-based inferences are provided to an information retrieval engine that retrieves a corresponding plurality of medical articles based on these knowledge-based inferences, and ranks each with respect to the knowledge-based inferences. A summary engine receives the ranked articles and creates a model based on the topical keywords and candidate sentences found in the highly ranked articles. A paraphrase engine processes the candidate sentences to provide a summary response based on a knowledge-based paraphrase model. An audio output device renders the summary report as the response to the user&#39;s original vocal query.
PROBLEM TO BE SOLVED: To obtain the subject activation agent composed of a cancerspecific protein or peptide originated from a cancer-relating gene, presenting an antigen by an HLA class II molecule and effective for inducing effective antitumor immunity by activating an antitumor immunity effecter mechanism. SOLUTION: This agent contains a cancer cell-specific protein and/or peptide originated from a cancer-relating gene product, forming a complex with the HLA class II molecule, inducing the proliferation response of a CD4&lt;+&gt; T cell specifically recognizing the complex and activating an antitumor immunity effecter mechanism. The cancer-relating gene is e.g. a cancer-suppressing variant gene such as p53 gene and Rb gene. The peptide can be produced e.g. by synthesizing an overlap peptide composed of about 20 residues based on the amino acid sequence of a cancer-relating gene product, directly bonding the peptide to an HLA molecule on an antigen-presenting cell, examining the reactivity of T cell and selecting the product having T cell epidope recognizing the T cell.
The invention relates to a method for improving methods of immunotherapy. The areas of application of the invention include the field of medicine and molecular biology. The aim of the invention is to provide a simple method for influencing ligand exchange of MHC molecules for the purpose of developing therapeutical methods. The invention is put into practice according to the claims. It is based on the surprising finding that ligand exchange of MHC molecules (MHC class II molecules and MHC class I molecules) is influenced by H bridge donors and acceptors. It was further surprisingly found that hydrogen bridge donors or acceptors also influence the exchange of larger ligands (preferably &gt; 3000 daltons, also &gt;10000 daltons), such as for example proteins or complex protein mixtures, on MHC molecules (MHC class II molecules and MHC class I molecules). Preferably ligand exchange is influenced by low-molecular H bridge donors or acceptors.
NEW MATERIAL:A 2-iminothiazolidin-4-one derivative expressed by formulaI (R is phenyl having two substituent groups selected from the group consisting of alkoxyl groups and hydroxyl groups on the ring or a methylenedioxy group at the adjacent positions on the ring). EXAMPLE:5-(3,4-Diethoxyphenyl)-2-imino-thiazolidin-4-one. USE:Useful as a synthetic intermediate for thiazolidine-2,4-dione derivatives useful for diabetic cataract, neuropathy, retinopathy, etc. of men or mammals. PROCESS:A compound expressed by formula II (R&lt;1&gt; is H or lower alkyl) is reacted with thiourea under acidic conditions, e.g. acetic acid or hydrochloric acid, in a solvent, e.g. methanol or tetrahydrofuran, usually at 70-100 deg.C to give the compound expressed by formulaI.
FIELD: medicine.SUBSTANCE: X-ray examination of a venous bed of an individual&#39;s rectum involves using 76% urografin. The inferior mesenteric vein stem and iliac vascular bundles from both sides are approached. They are catheterised and prepared by washing in 10% ammonia and distilled water. Before preparation, the inferior mesenteric vein is detected by a method of visualisation of the portal vein system. A green solution of brilliant green is inserted into its stem. The final stage is a direct X-contrast examination by fixed 12P9 Armobil-9 X-ray apparatus. 3 series of images are done. The first comparison X-ray represents plan radiography in a frontal projection of the small pelvis. The second X-ray is plan radiography in a frontal projection of the small pelvis with tight filling of the prepared bed of the rectal portal system with X-ray contrast 76% urografin. The third X-ray is plan radiography in a frontal projection of the small pelvis with tight filling of the internal iliac veins from both sides in a combination with X-ray contrast 76% urografin.EFFECT: method provides optimising the X-ray examination of the individual&#39;s rectal veins, visualising the vascular system adequately, ensuring the information concerning special characteristics of the vascular organometry, enables detecting the portocaval anastomosis by the optimum preparation of the vascular system, using urografin as the contrast substance and implementing the developed procedure of the X-ray examination.3 dwg, 1 ex
Novel hydroxyethylidene-cyanoacetic acid anilides of formula Ia or their tautomeric form Ib are prepared by reacting a dialkylaminoethylidene-acetic acid anilide first at -70 to +50 DEG C with chlorosulphonyl or fluorosulphonyl isocyanate and subsequently at -30 to +25 DEG C with a tertiary amine. The reaction is carried out in an inert aprotic solvent. The reaction mixture obtained is rendered weakly alkaline and the dialkylaminoethylidene-cyanoacetic acid anilide formed is isolated from the lypophilic phase and is hydrolysed. The symbols in formulae Ia and Ib have the meaning given in the patent claim. The compounds of formula Ia and Ib as well as their physiologically tolerated salts exhibit powerful antiphlogistic and analgesic, as well as anthelminthic, antimycotic and fungicidal effects. &lt;IMAGE&gt;
An extract of an Achillea sp. plant, an insoluble precipitate thereof and an active fraction thereof are provided to inhibit replication of hepatitis B virus and be non-toxic, thereby being usefully used as a pharmaceutical composition for preventing and treating hepatitis B virus. A pharmaceutical composition for preventing and treating hepatitis comprises an extract of an Achillea sp. plant, an insoluble precipitate generated by dissolving the extract in a lower alcohol, or an active fraction isolated from the insoluble precipitate using chromatography, wherein the Achillea sp. plant is selected from the group consisting of Achilla ptarmica subsp. macrocephala var. angustifolia Heim, Achillea acuminata (Lebeb.) Sch. Bio, Achillea acuminata Freyn, Achillea alpina L., Achillea alpina subsp. rhodoptarmica (Nakai) Kitam, Achillea alpina var, discoidea (Regal) Kitam, Achillea millefolium L., Achillea millefolium var. setacea (Waldst &amp; Koch), Achillea ptarmica L., Achillea ptarmica var. acuminata (Ledeb.) Heim, Achillea ptarmicoides Naxim., Achilla rhodoptarmica Nakai, Achilla setacea Waldst &amp; Kit, Achillea sibirica Ledet., and Achillea sibirica Var. discoidea Regal. Further, an extract solvent of the extract of the Achillea sp. plant is water, alcohol or a mixture thereof.
Graphical layouts, algorithms, and methods are introduced herein to implement user interfaces for mobile and/or wearable medical devices. In one aspect of the present invention, new graphical layouts are introduced for simplified presentation of time-dependent patient data. In another aspect of the invention, methods and algorithms are introduced to acquire, extract and present relevant features of patient data in real-time in order to simplify the graphical presentation and interpretation. In another aspect of the invention, elements of a multi-modal user interface are introduced in order to simplify and minimize the user&#39;s interaction with the medical wearable device. In yet another aspect of the invention, further methods are introduced for real-time interaction between a user or several users and a wearable or several wearable medical devices. In one embodiment of the present invention, a smartphone, a smart watch, a head-mounted device or similar devices can be used to acquire and display in real-time patient data, e.g., electrocardiogram and relevant features, e.g., heart rate, etc. In another embodiment of the present invention, smartphones, smart watches, head-mounted devices or similar devices can be used to share in real-time the patient data.
In prepn. of egg oil from hen&#39;s and/or other eggs, pref. cooled to low temp. or shock-frozen, (a) hydrocarbons, pref. white spirit and/or turpentine, and opt. water and/or alcohol, are added to and mixed with sepd. egg yolk or egg white, (b) the mixt. is heated with continuous movement, until (c) the egg oil, with residual solvent, settles on the surface of the mixt. and is sepd. from the rest of the mixt.. USE/ADVANTAGE - (i) The residual mixt. and/or oily/waxy components are used in prodn. of artists&#39; materials, (ii) egg yolk oil is used in paints and artists&#39; materials to alter the consistency, (iii) egg white oil is used to reinforce the luminosity of paints and lacquers, (iv) egg yolk oil and egg white oil are mixed with drying oils, resin solns., glycerides, solvents, water, binders, emulsions, lacquers, adhesives and synthetics, as protectants and impregnants, (v) egg yolk oil is used as coolant and lubricant, and (vi) egg yolk oil is used as basis for cosmetics, and for compsns. for care and polish of metal or lacquered surfaces. Other applications are: (vii) extractant for obtaining extracts from dried fruit, comprising a mixt. of egg yolk oil, balsam turpentine oil and distilled water, (viii) emulsion paint, as artists&#39; material, comprising a mixt. of egg white oil with an acrylic binder, and opt. with hydrolysed starch, pref. rice starch, (ix) protectant and impregnant for wood comprising a mixt. of 1 pts. of egg white oil and 5-20 pts. of amaryllis oil, and (x) compsn. for coating printing plates comprising an egg oil emulsion with 10-25 vols.% of porcelain powder in distilled water and/or copa lacquer. Eggs are used industrially in a simple process. The oils can be mixed at once, hot or cold, with the emulsions, binders, artists&#39; materials, pastes or ointments, giving good viscosity, uniformity, stability and keeping properties. Egg yolk oil combines high heat resistance, good heat conductivity and high specific heat with good slip and lubricant action. The wood protectant is liq. and easily sprayed, and has good preservative power. The compsn. for coating printing plates is a paste, easily applied with a spatula, and very hard after baking
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a transmission service method that enables a doctor, etc., of a hospital to obtain secret document data such as a necessary medical chart in a short time and to acquire the details of the secret document data as a high-definition image, and to provide a device therefor.  &lt;P&gt;SOLUTION: When a page turn instruction 37 is given from a document data browsing terminal on the hospital&#39;s side, documents such as the medial charts set in an automatic document turn device 14 on the side of a warehouse company are turned. A moving image acquisition device 15 photographs data of the turned documents and transmits it in moving images. The moving images are displayed on a moving image display part 32. When a still image acquisition instruction 34 is given on the hospital&#39;s side, a still image acquired by a still image acquisition part 43 is encoded in a still image encoding part 44, transmitted to the hospital&#39;s side and displayed on a still image display part 39. When a camera control instruction 36 is given, control such as the position of a television camera of the moving image acquisition device 15, zoom-in, etc., is performed.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
Benzoxazoles and benzthiazoles of the general formula &lt;FORM:0974365/C1/1&gt; wherein A is an oxygen or a sulphur atom, R is a 5-membered heterocyclic ring containing an oxygen, sulphur or nitrogen atom as the sole heteroatom, each of R1 and R2 is a hydrogen atom or a C1-5 alkyl, C1-5 alkoxy, C1-5 alkylthio, aryloxy or arylthio radical; or, R1 and R2 together represent the 1, 4-butadienyl radical may be prepared by: (A) the reaction of an o-aminophenol or o-aminothiophenol with a heterocyclic carboxylic acid; when the substituents in the 5- and/or 6-positions are alkyl, alkoxy, aryloxy, alkylthio or arylthio substituents, the phenol derivatives are substituted with such groups in the 4 and/or 5 positions; (B) by the same reaction using the acid halide, lower alkyl ester, amide or nitrile in place of the heterocyclic free carboxylic acid; (C) by reaction of the o-amino-phenol or -thio-phenol with an aldehyde derivative of the heterocyclic ring compound.  Specific examples relate to the preparation of 2-(21-thienyl)-benzoxazole and 2-(21-furyl)-benzoxazole by method (A) above and 2-(21-pyrryl)-benzothiazole by method (C) above, 2(21-pyrryl)-benzothiazoline being formed as an intermediate and converted to the required compound by treatment with ferric chloride in ethanol.ALSO:Anthelmintic compositions comprise an orally ingestible diluent in which is uniformly distributed a compound of the general formula &lt;FORM:0974365/A5-A6/1&gt; wherein A is an oxygen or sulphur atom, each of R1 and R2 is a hydrogen atom or a C1-5 alkyl, C1-5-alkoxy, C1-5 alkylthio, aryloxy or arylthio group or R1 and R2 together represent a 1,4-butadienyl radical and R is a 5-membered heterocyclic ring containing an oxygen, sulphur or nitrogen atom as the sole hetero atom.  The compositions may be in conventional veterinary forms, e.g. a bolus or drench or they may be in the form of an animal feedstuff, salt-block, premixes or feed supplements, e.g. a protein and vitamin supplement for use as a &#34;top dressing&#34; for feeds of the larger domesticated animals.  The invention also comprises the process of combating helminthiasis in commercially reared animals by administering the compositions or active compounds of the invention.